Stocks / NASDAQ / AlphaTON Capital Corp.

AlphaTON Capital Corp.

Industry: Finance – Asset Management

Stock Symbol: ATON – NASDAQ

Animal Usage: Animal Testing, Tangential

Our Opinion

AlphaTON Capital can be accurately described as both a TON-focused digital asset and blockchain infrastructure company and a company that remains involved in biopharmaceutical R&D through its oncology subsidiary Cyncado Therapeutics, which participates in preclinical animal studies conducted in mouse cancer models.

Supporting Evidence:

AlphaTON Capital Corp. confirms the use of animal testing for its oncology drug candidates in official corporate disclosures.

“Preclinical data showed TT-4 achieved greater than 90% tumor growth inhibition in mouse mesothelioma models when combined with anti-PD1 antibody, with 60% complete responses and greater than 90-day survival in combination treatment groups.” Read the article for more details

Company Description

AlphaTON Capital Corp. operates as a digital asset treasury company. It focuses on building and managing a strategic reserve of The Open Network (TON) tokens and developing the Telegram ecosystem. However, the company maintains a “legacy business” in the biopharmaceutical sector. This legacy division actively develops immuno-oncology therapies (such as PORT-2 and PORT-3) which inherently involve preclinical animal testing and clinical research to evaluate drug safety and efficacy. AlphaTON Capital Corp owns and operates the related entities, with Tarus Therapeutics, LLC (dba Cyncado Therapeutics) functioning as a wholly owned subsidiary under the AlphaTON corporate umbrella. The company was formerly known as Portage Biotech Inc. and changed its name to AlphaTON Capital Corp. in September 2025.

Company Website: https://alphatoncapital.com

Contact: ir@alphatoncapital.com